Stay updated with breaking news from Carsten tsch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Cardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditis proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
The reckless approach of governments at all levels in lifting the remaining coronavirus protections despite the enormous excess mortality illustrates the indifference of the ruling class to human life. ....
Analyst: Julien Desrosiers; Felix Haugg The Company announced topline results from its Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a pharmaceutically produced oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease. These results positively support Cardiol Therapeutics proposed treatment dosage for their upcoming CardiolRx Phase II and Phase II/III trials. David Elsley, President and CEO of Cardiol Therapeutics, stated: Cardiol is initiating a Phase II/III clinical trial in the U.S. investigating the cardioprotective properties of CardiolRx in 422 hospitalized patients with COVID-19 with a prior history of, or risk ....
Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A Cardiol Therapeutics Inc. ( a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management s Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company s profile on SEDAR at www.sedar.com and on the Company s website at www.cardiolrx.com. David Elsley, President and Chief Executive Officer of Cardiol, commented: 2020 was a very exciting year for Cardiol Therapeutics. We made extraordinary progress in our research and clinical development programs, while significantly strengthening our financial position. We are particularly excited about the progress made across our research and development programs supporting the development of CardiolRx, our pharmaceutically produced extra- ....